• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Evotec to close Indian chemistry operations

Evotec to close Indian chemistry operations

July 8, 2013
CenterWatch Staff

Hamburg, Germany-based Evotec will close its chemistry operations in Thane, India. All chemistry work now will be performed at its Abingdon, U.K., facility, to address to an increasing requirement to operate closer to the principal R&D laboratories of major customers. All project work in Thane will be completed by the end of September, and Evotec (India) Private will then wind down.

As a result, the company will cut 120 people and Evotec will take a one-time impairment charge.

“Evotec was due to relocate its Indian chemistry operations in June 2014,” said Dr. Mario Polywka, COO of Evotec. “During the due diligence in finding a new facility and because of growing customer requirements for European-based activities, we came to the conclusion to exit our operations in India completely. Through this realignment we will be able to most efficiently serve our customers, utilize our U.K. chemistry resources and capabilities and also realize some cost savings. Unfortunately, the impact is that we must say goodbye to a first-class work force in Thane that has so ably supported our customers over the last four years.”

Evotec (India) Private is a 100% subsidiary of Evotec. Its offerings include custom synthesis, process research and development, scale-up and analytical services.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing